Lybalvi mechanism of action?

Lybalvi is a fixed-dose combination of olanzapine and samidorphan.

- Olanzapine: An atypical antipsychotic that works mainly by antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors in key brain pathways (mesolimbic and mesocortical). It also blocks several other receptors (5-HT2C, 5-HT6, H1, α1, muscarinic), which contributes to its antipsychotic effects as well as metabolic and sedative side effects.

- Samidorphan: A selective μ-opioid receptor antagonist. By blocking μ-opioid receptors, it aims to reduce the weight gain and metabolic side effects often seen with olanzapine, likely by modulating the endogenous opioid system involved in appetite and reward.

In short, olanzapine provides the antipsychotic effect, while samidorphan mitigates olanzapine-associated weight gain without expectedly diminishing antipsychotic efficacy. If you’d like, I can summarize this for dosing labels or patient-friendly language.